-

Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:

  • William Blair Growth Stock Conference on Thursday, June 9 in Chicago; presentation at 1:20 p.m. Central Time.
  • Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14 in Rancho Palos Verdes; fireside chat at 10:40 a.m. Pacific Time.

The presentations will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the presentations will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Contacts

For Twist Bioscience
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
media@twistbioscience.com

Twist Bioscience Corporation

NASDAQ:TWST

Release Versions

Contacts

For Twist Bioscience
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
media@twistbioscience.com

More News From Twist Bioscience Corporation

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to support the advancement of pharmaceutical and biotech customers’ pre-clinical studies. “Our new plasmid preps combine the quality and consistency needed for preclinical research with the speed and cost efficiency customers have come to expect from Twist,” said Emily M. Leproust, CEO and co-founder of Tw...

Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2025 ended September 30, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2025 earnings report and the investor presentatio...

Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist, will participate in a fireside chat at the at 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 3:20 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “Inves...
Back to Newsroom